Profit and Loss Results Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2025 is 12.33% vs NA in Mar 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2025 is 53.23% vs NA in Mar 2024
Interest
YoY Growth in year ended Mar 2025 is 120.78% vs NA in Mar 2024
Profit After Tax
YoY Growth in year ended Mar 2025 is 63.96% vs NA in Mar 2024
Compare Profit and Loss Results of Symbiotec Pharma
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
756.00
1,837.00
-1,081.00
-58.85%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
756.00
1,837.00
-1,081.00
-58.85%
Expenditure (Ex Depriciation)
Stock Adjustments
11.00
136.00
-125.00
-91.91%
Raw Materials Consumed
288.00
760.00
-472.00
-62.11%
Power & Fuel Cost
0.00
14.00
-14.00
-100.00%
Employee Cost
119.00
185.00
-66.00
-35.68%
Operating Expenses
50.00
22.00
28.00
127.27%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
2.00
88.00
-86.00
-97.73%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
17.00
40.00
-23.00
-57.50%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
537.00
1,346.00
-809.00
-60.10%
Operating Profit (PBDIT) excl Other Income
219.00
491.00
-272.00
-55.40%
Other Income
32.00
19.00
13.00
68.42%
Operating Profit (PBDIT)
251.00
511.00
-260.00
-50.88%
Interest
16.00
1.00
15.00
1,500.00%
Profit before Depriciation and Tax
234.00
509.00
-275.00
-54.03%
Depreciation
38.00
37.00
1.00
2.70%
Profit Before Taxation & Exceptional Items
196.00
472.00
-276.00
-58.47%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
196.00
444.00
-248.00
-55.86%
Provision for Tax
50.00
118.00
-68.00
-57.63%
Profit After Tax
145.00
326.00
-181.00
-55.52%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
589.00
445.00
144.00
32.36%
Profit Available for appropriations
734.00
772.00
-38.00
-4.92%
Appropriations
734.00
772.00
-38.00
-4.92%
Equity Dividend (%)
0%
1230%
-1,230.00
Earnings Per Share
133.35
141.85
-8.50
-5.99%
Profit And Loss - Net Sales
Net Sales 756.68 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 12.33% vs NA in Mar 2024
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 219.03 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 53.23% vs NA in Mar 2024
Profit And Loss - Interest
Interest 16.65 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 120.78% vs NA in Mar 2024
Profit And Loss - Profit After Tax
Profit After Tax 145.83 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 63.96% vs NA in Mar 2024
Footer loading
